Perceptions and current practices of community pharmacists regarding antimicrobial stewardship in Tasmania

Tasneem Rizvi1 · Angus Thompson1 · Mackenzie Williams1 · Syed Tabish Razi Zaidi1,2

Received: 19 February 2018 / Accepted: 20 July 2018 / Published online: 2 August 2018 © The Author(s) 2018

Abstract

Background Despite increasing interest in antimicrobial stewardship (AMS), little is known about the related practices and perceptions of community pharmacists. Objective To develop and validate a questionnaire to measure the current practices of, and barriers to community pharmacists’ participation in AMS. Setting Community pharmacists in Tasmania, Australia. Method A questionnaire to explore AMS knowledge, current practices and perceptions of community pharmacists was developed. It was designed after rigorous literature review, expert opinion, and feedback from a group of community pharmacists. A convenience sample of 140 Tasmanian community pharmacists was used for this study. Cronbach’s alpha and exploratory factor analysis (EFA) were used for reliability and validity. The questionnaire was hosted online, a link to which was sent by invitation e-mails, fax and post to community pharmacists in Tasmania, Australia. Main outcome measure Current AMS practices, perceived importance, barriers and facilitators of AMS. Results Eighty-five pharmacists responded to the survey yielding a response rate of 61%. EFA identified one factor solution for each of three perceptions scales and showed acceptable reliability. The Cronbach’s alpha of perceived importance-understanding was 0.699, perceived importance-motivating was 0.734, perceived support from GPs was 0.890, operational barriers was 0.585, general facilitators was 0.615. Most pharmacists reported that they counselled patients on adverse effects (86%), drug interactions (94%), and allergies (96%). In contrast, less than half (43%) intervened with prescribers regarding antibiotic selection. Lack of training, lack of access to patients’ records, limited interactions with general practitioners and absence of a reimbursement model were major barriers limiting community pharmacists’ participation in AMS. Conclusion The questionnaire was of acceptable reliability and validity; a larger study will further contribute in its reliability and validity. Future studies utilising the questionnaire at national and international level may provide further insights into the determinants of community pharmacist’s involvement in AMS.

Keywords Antimicrobial · Australia · Perception · Pharmacist · Practice · Antimicrobial stewardship · Survey

Impact of findings on practice statements

• An improved understanding of routine practices and perceptions of community pharmacists related to antimicrobial stewardship can assist in the development and implementation of antimicrobial stewardship related initiatives in community settings.
• Community pharmacists are willing and capable of playing an important role in helping optimise antimicrobial use by educating patients and effectively interacting with prescribers, though a number of barriers may currently be limiting their participation.
• Knowledge surrounding current practices and perceptions of community pharmacists regarding antimicrobial stewardship is limited. Future research into the barriers to and facilitators of community pharmacists optimising antimicrobial use is required.

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s11096-018-0701-1) contains supplementary material, which is available to authorized users.

*Syed Tabish Razi Zaidi s.t.r.zaidi@leeds.ac.uk

1 Department of Pharmacy, School of Medicine, University of Tasmania, Hobart, Australia
2 School of Healthcare, University of Leeds, Leeds, UK
Introduction

Increasing antimicrobial resistance (AMR) is a major global threat to human health [1]. If not tackled urgently AMR will cause 10 million deaths annually by 2050 [2]. Antimicrobial stewardship (AMS) refers to the coordinated interventions designed to measure and improve the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug, dose, duration of therapy, and route of administration [3]. AMS is high on the agenda of global health organisations and currently there is an increasing interest in community-based AMS initiatives, as this is where the majority of antibiotic use occurs, much of which is inappropriate [4].

Community pharmacists can play an integral role in AMS programs within community settings for various reasons. Firstly, pharmacists are delivering value-added services beyond their traditional dispensing duties [5]. Secondly, they are one of the most frequently seen healthcare professionals and serve as the first point of contact for seasonal viral respiratory tract infections—the most common conditions where inappropriate use of antibiotics has been noted [6]. Thirdly, community pharmacists often liaise between patients and various service providers, and are well positioned to operationalise any AMS framework. Little is known about the current practices of community pharmacists in the developed world. An improved understanding of these issues can assist in the development and implementation of AMS initiatives in community settings. Some of the previous studies were conducted in countries where antibiotic prescribing and dispensing are neither reimbursed nor well regulated thus making the research findings less applicable in developed countries [7, 8].

In Australia, approximately 27 million antibiotic prescriptions are dispensed annually [9] and antimicrobial use is 20% above the average of countries in the Organisation for Economic Cooperation and Development [10]. To address this issue, the Australian government released its first antimicrobial resistance strategy in the year 2015 [11]. The Australian government-funded National Prescribing Service MedicineWise (NPS-MW) is playing an important role to reduce antibiotic use in the community raising awareness through educational initiatives such as the “resistance fighter campaign” and “antibiotic awareness week” [12]. In Australia, strict regulatory restrictions exist and antibiotics cannot be dispensed without a prescription [13]. However, once a prescription is issued, it is generally valid for 1 year and in many cases prescribing software automatically defaults to including a repeat. Furthermore, dispensing software in Australian community pharmacies have no interface with the prescribing software and therefore, pharmacists cannot access a patient’s clinical information or laboratory data [13]. This further limits Australian community pharmacists participation in AMS initiatives. Little is known about the current practices and perceptions of pharmacists working in the community sector.

The primary aim of our study was to develop and validate a questionnaire to measure the perceptions and practices of Australian community pharmacists regarding AMS. A secondary aim was to determine community pharmacist’s awareness of and engagement with NPS-MW’s initiatives designed to reduce AMR. The study was conducted in the Australian state of Tasmania, which has a population of around 520,000 and a geographical area similar to that of the Republic of Ireland. The study findings can help to inform AMS frameworks for community pharmacists in Australia.

Ethics Approval

This study received approval from Tasmanian Human Risk Ethics Committee (HREC) in April 2016 (H0015673).

Method

Survey development

We generated an item pool based on a thorough literature review with key words related to antimicrobial stewardship, community, and pharmacists [7, 11, 14–20]. STRZ reviewed, modified and organised this item pool according to Australian pharmacy practice. A demographic section was also introduced at this stage. The questionnaire was then reviewed by AT and a section on items related to the NPS-MW initiatives was included. Following the initial review, the questionnaire was edited, based on limited piloting on researchers and practising pharmacists working in the Division of Pharmacy at the University of Tasmania. The final questionnaire is available as supplementary material. A Likert-type agreement scale was used for questions around current practices and perceptions.

Survey deployment

The questionnaire was hosted online using the Lime Survey® portal. A convenience sample of 140 community pharmacists across Tasmania was invited to participate in the study via e-mail, fax and post during the first week of May 2016. Subsequently copies of questionnaire with a standard invitation letter were faxed and posted to pharmacies where there had been no initial response. The invitation letter included a web link to the questionnaire, a mobile-enabled scanning code (QR code) directing participant to the questionnaire
site, and a paper survey with a self-addressed reply paid envelope. Two reminders were sent on a fortnightly basis after faxing/posting. Participants were offered the chance to win one of five gift cards selected by a draw conducted at the end of the study.

Data analysis

Exploratory factor analysis (EFA) was used to examine the internal structure and construct validity of the perception scales. Maximum likelihood technique with the oblique rotation was employed. The items having a rotated factor loading of at least 0.55 or above [21] were retained for each factor. Qualitative feedback from the participants was discussed amongst the investigators where loadings were ambiguous. Cronbach’s alpha was used to determine the reliability of individual factors. Qualitative comments were analysed using a constant comparative approach to identify various themes under the guidance of STRZ without any specific software. Univariate linear regression was employed to identify variables and factors associated with the participants’ scores on the current AMS practices section of the survey. Variables with a \( p \) value \( \leq 0.20 \) were included in the multivariate linear regression model. All statistical analyses were performed using SPSS version 22 (IBM Inc., Chicago, IL).

Results

Eighty-five of the 140 community pharmacists responded to the survey yielding a response rate of 61% with the majority of respondents being female (65%) (Table 1). A wide distribution of age and experience was noted among the participants ranging from 23 to 70 years and 1–50 years respectively. Most participants (80%) had an undergraduate pharmacy degree as their highest qualifications.

Validity and reliability of the survey tool

Appendix 1 in “Electronic supplementary material” shows the results of EFA and Appendix 2 in “Electronic supplementary material” shows the results of reliability analysis including total item statistics. The rotated solution for the perceived importance scales showed two factors comprising of perceived understanding of AMS and perceived motivating factors of AMS (Cronbach Alpha 0.699 and 0.734 respectively). The EFA of perceived barriers scale yielded a two-factor solution comprising of perceptions regarding support from GPs and operational barriers (Appendix 1 in “Electronic supplementary material”). The Cronbach’s alpha of the perceived support from GPs and the operational barriers scale was 0.89 and 0.58, respectively. The EFA of perceived facilitators scale yielded one-factor solution. The Cronbach’s alpha of the general facilitators’ scales was 0.615. Items on monetary compensation and public image of pharmacists’ role in AMS were retained because of a strong support from the qualitative feedback on these issues.

Results of the study

Awareness of NPS-MW initiatives

The majority (63%) of pharmacists knew the term ‘antimicrobial stewardship’, although 75% reported an improved understanding after reading the provided definition. Most respondents were aware of the general (80%) and specific (72%) NPS-MW quality initiatives, though less than half (45%) were aware of the resources available to them. Around a quarter of the respondents reported that they are taking more interest (24%) and making more interventions (27%) regarding antibiotic use due to the NPS-MW’s initiatives. Lastly, nearly half of the participants (53%) reported that they would be willing to participate in the future AMS initiatives if resources are made available.

Current practices of AMS

Pharmacists frequently contacted prescribers relating to allergies, dosing, or drug interactions (Table 2). On the
contrary, pharmacists less commonly contacted prescribers if they considered the choice of antibiotic to be inappropriate. Respondents indicated that they were referring patients to see GPs if they suspected an infectious presentation that might need an antibiotic prescription, but where this was not the case Pharmacists reported that they were invariably managing patients by offering over the counter medicines (95.8%). Pharmacists were commonly ascertaining the need for an antibiotic when a patient presented a repeat prescription (82.9%).

### Table 2  Current AMS practices of Tasmanian community pharmacists

| Scale and items | Participant’s response, % | Median (IQR) |
|-----------------|---------------------------|--------------|
|                 | Scoring ≤ 3 | Scoring ≥ 4  |              |
| Current AMS practices |                   |              |
| Providing clear messages on expected side effects (n = 72) | 13.9 | 86.1 | 4 (4–5) |
| Providing clear messages what should be done if patient experience side effect (n = 72) | 22.2 | 77.8 | 4 (4–5) |
| Contacting the prescriber if the patient is allergic to the prescribed antibiotic (n = 72) | 1.4 | 98.6 | 5 (5–5) |
| Contacting the prescriber if the antibiotic dose/frequency is too high or too low (n = 71) | 14.1 | 85.9 | 5 (4–5) |
| Contacting the prescriber if the prescribed antibiotic involves a drug interaction (n = 70) | 2.9 | 97.1 | 5 (5–5) |
| Contacting the prescriber if the choice of antibiotic may not be optimal (n = 71) | 53.5 | 46.5 | 3 (2–4) |
| Recommending OTC/self-care treatment to patients with symptoms of infection not needing antibiotics (n = 71) | 4.2 | 95.8 | 5 (4–5) |
| Referring patients to a general practitioner when symptoms are suggestive of an infection (n = 69) | 1 | 99 | 5 (5–5) |
| Providing advice when it would be appropriate to use the repeat (n = 70) | 17.1 | 82.9 | 4 (4–5) |
| Discussing with patient to determine if it is appropriate for them to use the presented repeat (n = 72) | 30.6 | 69.4 | 4 (3–5) |

Current practices measured on a scale of 1–5, where 1 = do not practice at all and 5 = practice all the time

n Number of participants, IQR inter quartile range

### Table 3  Perceived importance and barriers to participate in AMS in community pharmacy

| Scales and items | Participant’s response, % | Median (IQR) |
|-----------------|---------------------------|--------------|
|                 | Scoring ≤ 4 | Scoring ≥ 5  |              |
| Perceived importance of AMS-understanding of the role |                   |              |
| Community pharmacist can play an important role in AMS (n = 68) | 2.9 | 97.1 | 7 (5–7) |
| AMS will reduce health care costs associated with infections (n = 68) | 21.6 | 78.4 | 7 (5–7) |
| AMS will reduce inappropriate antibiotic use (n = 68) | 17.6 | 82.4 | 5 (5–7) |
| Perceived importance of AMS-motivating forces |                   |              |
| AMS will enhance the public image of pharmacists (n = 67) | 20.9 | 79.1 | 6 (5–7) |
| AMS will enhance the job satisfaction of pharmacists (n = 67) | 17.9 | 82.1 | 6 (5–7) |
| Perceived barriers of AMS-operational barriers |                   |              |
| I do not have the required training to participate in AMS (n = 66) | 63.6 | 36.4 | 4 (3–5) |
| I do not have enough time to participate in AMS (n = 64) | 75 | 25 | 3 (3–5) |
| Limited access to patient record to review the appropriateness of antibiotic prescriptions (n = 65) | 4.6 | 95.4 | 6 (5–7) |
| There aren’t any standard guidelines to implement AMS (n = 62) | 33.9 | 66.1 | 5 (4–6) |
| Perceived barriers of AMS-perceived support from GPs |                   |              |
| GPs are not receptive to pharmacists intervening on the choice of antibiotic (n = 63) | 34.9 | 65.1 | 5 (5–6.25) |
| GPs are not receptive to pharmacists intervening on the dose and dosage form of antibiotic (n = 64) | 64.1 | 35.9 | 3 (3–6) |
| GPs are not receptive to pharmacists intervening on the duration of antibiotic (n = 62) | 75.8 | 24.2 | 3 (3–6) |

Perceived importance and perceived barriers were measured on a scale of 1–7, where 1 = strongly disagree and 7 = strongly agree

n Number of participants, IQR inter quartile range
that they could play an important role in implementing AMS initiatives and their participation in AMS programs would lead to a better public image and enhanced job satisfaction. Pharmacists also indicated that the lack of access to patients’ medical records and objective laboratory information limited their participation in AMS. Pharmacists also felt that GPs do not welcome their intervention regarding choice of antimicrobial prescription (Median = 5, IQR 5–6.25 Scale 1–7). On the contrary, interventions related to the dose, duration or dosage form of antibiotics were perceived as welcomed by GPs. Pharmacists were mostly neutral about the lack of training as a barrier to their participation in AMS. Likewise, most of them did not consider lack of time as a barrier in their AMS role (Table 3). Facilitators related to public awareness campaigns, collaboration with GPs, access to antibiotic guidelines and patients’ clinical and laboratory data, were all considered as most helpful in increasing pharmacists’ AMS involvement (Table 4).

The univariate linear regression analysis identified three variables that showed some degree of association with the total scores for the AMS practices section of the survey (p value ≤ 0.2). The three variables were willingness to participate in the future AMS initiatives, total scores of general facilitators scale and perceived importance scale. The multivariate linear regression analysis did not identify any of these variables having a significant association with the AMS practices of the community pharmacists (Table 5).

### Qualitative feedback

Qualitative comments were analysed using a constant comparative approach to identify various themes under the guidance of STRZ. Pharmacists showed great interest in providing qualitative feedback via free text comments. The main themes from the qualitative feedback were contextual limitations of community pharmacists, improper use of repeat prescriptions, need of public awareness, lower than recommended dose of antibiotics in children and impact of AMS on business model of pharmacy. Software was not used for qualitative analysis. Details of these comments are presented as Table 6.

### Discussion

We report the development and validation of the first questionnaire to measure the current practices and perceptions of AMS amongst Australian community pharmacists. The mixed method approach of using EFA, expert opinion and qualitative feedback to validate the survey tool was found useful in retaining important items for each section, yet reducing the size of the questionnaire to a manageable length. The three perception scales demonstrated

| Table 4 | Perceived facilitators of AMS in community pharmacy settings |
|----------|-------------------------------------------------------------|
| Scales and items | Participant’s response, % | Median (IQR) |
| | Scoring ≤ 3 | Scoring ≥ 4 |
| Perceived facilitators of AMS-General facilitators | | |
| Increased provision of education activities regarding AMS (n=65) | 6.2 | 93.8 | 5 (4–5) |
| Better collaboration with local GP practices (n=65) | 1.5 | 98.5 | 5 (4–5) |
| Clarifications of the duties of pharmacists’ professional organizations (n=63) | 27 | 73 | 4 (3–5) |
| Better access to patient’s clinical and laboratory data (n=64) | 7.8 | 92.2 | 5 (4–5) |
| Perceived facilitators of AMS-operational facilitators* | | |
| Public awareness initiatives highlighting community pharmacists in AMS (n=66) | 10.6 | 89.4 | 5 (4–5) |
| Monetary compensation for the time involved in AMS programs (n=64) | 18.8 | 81.2 | 4 (4–5) |

Perceived facilitators measured on a scale of 1–5, where 1 = Unhelpful and 5 = most helpful
n Number of participants, IQR Inter quartile range
*Items not loaded on any factor but retained based on qualitative analysis as participants were very vocal about the issues covered by these items

| Table 5 | Multivariate linear regression analysis: predictors of Tasmanian Community Pharmacists’ participation in AMS (n=59) |
|----------|---------------------------------------------------------------------------------------------------------------|
| Predictor | Unstandardised β | Standardised β | P value | 95% CI range |
| Willingness to participate in future AMS initiatives | 0.13 | 0.05 | 0.07 | −0.56–0.82 |
| Total scores on the perceived importance scale | 0.53 | 0.25 | 0.20 | −0.06–1.12 |
| Total scores on the general facilitators scale | 0.46 | 0.17 | 0.70 | −0.25–1.18 |
reasonable internal validity as evident from the results of EFA and an acceptable reliability demonstrated by a Cronbach’s alpha of > 0.5 [21]. Khan et al. [7], Erku [8] and a recent study by Sarwar et al. [22] have surveyed Malaysian, Ethiopian and Pakistani community pharmacists about AMS respectively. The contexts of pharmacy practice in these countries are significantly different to those found in most Western countries, including Australia where antibiotics are available only with a valid prescription. Additionally, based on the reported results, the authors have not conducted a formal exploratory factor analysis to examine the internal structure of the questionnaire.

**Principal findings of the pilot survey**

Our findings highlight that Australian pharmacists contribute to triaging common infectious presentations, determining those conditions that may require medical attention and those which are minor ailments amenable to self-care or management with over the counter medicines. This particular role of community pharmacists is not as widely appreciated in Australian settings as it has been in other countries. For example, provision of advice for minor ailments is considered a reimbursable activity in the United Kingdom [23]. We found that pharmacists were less comfortable about intervening with the choice of antibiotics or advising patients on the use of repeat prescriptions when
compared to other activities such as intervening on the dose and duration of antibiotics and counselling patients regarding the adverse effects of antibiotics. Qualitative comments further provided clarification about the contextual limitations of the Australian community pharmacy practice in determining the appropriateness of antibiotics or contacting GPs for interventions related to paediatric antibiotic dosing. These findings are not surprising, as community pharmacists in Australia do not have access to a patient’s clinical and laboratory data. Additionally, unlike the UK and most of Scandinavia, community pharmacies in Australia do not operate within a healthcare network which may be limiting one-on-one interaction between GPs and pharmacists [24].

Most pharmacists in this study rated the importance of AMS highly, considering it a source of motivation and learning, potentially enhancing the public image of the profession. Likewise, pharmacists also believed that AMS programs in the community will reduce inappropriate antibiotic use and healthcare costs. Our results are consistent with the study of Burger et al. [25] where the majority of respondents indicated that AMR is a worldwide problem and pharmacists have an important role to play in tackling this problem. The perceived barriers pharmacists reported in the study included lack of access to patient’s clinical and laboratory data and lack of co-operation from the GP when the community pharmacist intervenes regarding selection of antibiotics, both of which can be inter-related. Our findings are in line with a systematic review by the National Institute of Health Research, England [26] which reported that barriers to implementing AMS include lack of resources, patients’ expectations regarding antibiotics and the influence of colleagues on the selection of antibiotics. Most of the respondents believed that educational activities targeted towards pharmacists and patients will enable them to perform AMS duties efficiently. Similarly, most of the community pharmacists suggested improved collaboration with prescribers and patients’ clinical and laboratory data would be helpful and enable them to better participate in AMS. This is consistent with the updated statement from the International Pharmaceutical Federation which stressed the importance of pharmacist and public educational initiatives in implementing AMS [27].

**Awareness of AMS and national quality initiatives**

The findings of the pilot study identified a gap between AMS awareness and utilisation of available resources by community pharmacists. More efforts to engage pharmacy students, interns and pharmacists are required to develop community pharmacist’s competency in AMS. The majority of respondents were not regularly referring to the resources and activities of NPS-MW. Almost half of the respondents reported that they are not currently utilising the educational resources available to them but would definitely employ these if they get its easy access. Globally an increasing number of learning and training courses and toolkits are offered by public and private organisations, institutions and countries [28–31], some of which are free web-based online courses and others are inter-professional curriculums to increase pharmacists’ competency in AMS. There is a clear a need for such initiatives to help bridge this AMS knowledge gap for Australian community pharmacists.

**Limitations and strengths**

The findings of our study should be interpreted with some caution. We only examined the views of pharmacists from one Australian state (Tasmania) and the views may not be generalizable to all Australian community pharmacists. Given the traditionally poor response rate with survey studies, we utilised a convenient sample of pharmacists drawn from a pool whose details are on file in the Division of Pharmacy, at the University of Tasmania, and this may further limit the generalisability of our findings. In contrast, a few specific strengths of the study should also be highlighted. To the best of our knowledge, this is the only study to report the development and validation of a questionnaire to measure community pharmacists’ perceptions of, and barriers to AMS in the community setting. We employed a robust process combining quantitative and qualitative data while supplementing it with expert opinion to develop and refine the questionnaire.

**Conclusion**

The newly developed questionnaire to measure pharmacists’ perceptions of and barriers to, AMS in community settings demonstrated acceptable reliability and validity. Pharmacists were supportive of their involvement in the AMS, though they highlighted some important barriers limiting this involvement. A future Australia-wide study, employing the newly developed tool, will provide more data to examine the questionnaire’s reliability and validity while providing further insights into the perceptions and practices of community pharmacists regarding AMS at a national level.

**Acknowledgements** The authors would like to acknowledge all the community pharmacists, research students, teachers, experts and Pharmaceutical Society of Australia (Tasmania Branch) who supported, participated in the survey and gave feedback for this study. The authors also like to thank Division of Pharmacy, School of Medicine, University of Tasmania, for arranging pre-paid gift vouchers for the winners of the survey draw.

**Funding** The Division of Pharmacy, School of Medicine, University of Tasmania, funded the pre-paid gift vouchers for the survey draw, through an internal research fund for the postgraduate students.
Conflicts of Interest None.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. World Health Organization. Antimicrobial resistance: global report on surveillance. France: WHO Press; 2014. http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf.

2. Shallcross LJ, Howard SJ, Fowler T, Davies SC. Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140082.

3. Infectious Diseases Society of America Emerging Infections N. Promoting antimicrobial stewardship in human medicine 1300 Wilson Boulevard Suite 300 Arlington, VA 22209 Emerging Infections Network.; http://www.idsociety.org/stewardship_policy.

4. Health S. Antimicrobial stewardship (AMS) SA Health: SA Health; 2016 (updated 11 July 2016). http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+4+health+internet/clinical+resources/clinical+programs/antimicrobial+stewardship.

5. Winslade N, Tambah R. Determinants of community pharmacists’ quality of care: a population-based cohort study using pharmacy administrative claims data. BMJ Open. 2017;7(9):e015877.

6. Kenealy T, Arroll B. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD000247.pub3.

7. Khan MU, Hassali MA, Ahmad A, Elkalmi RM, Zaidi ST, Dhingra S. Perceptions and practices of community pharmacists towards antimicrobial stewardship in the state of Selangor, Malaysia. PLoS ONE. 2016;11(2):e0149623.

8. Erku DA. Antimicrobial stewardship: a cross-sectional survey assessing the perceptions and practices of community pharmacists in Ethiopia. Interdiscip Perspect Infect Dis. 2016;2016:5686752.

9. Lum EPM, Page K, Nissen L, Doust J, Graves N. Australian consumer perspectives, attitudes and behaviours on antibiotic use and antibiotic resistance: a qualitative study with implications for public health policy and practice. BMC Public Health. 2017;17(1):799.

10. Australian Government DoH. Antimicrobial resistance (AMR) 2015 (cited 2016 26/02). http://www.health.gov.au/internet/main/publishing.nsf/Content/ohp-amr.htm.

11. Goff DA, Kullar R, Goldstein EJ, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis. 2017;17(2):e56–63.

12. MedicineWise. N. Duration of antibiotic therapy and resistance 2013 (updated 2016; cited 2016 13/03/2016). https://www.nps.org.au/medical-info/clinical-topics/news/world-antibiotic-awareness-week-handle-antibiotics-with-care.

13. Thompson A, Copping S, Stafford A, Peterson G. Repeatable antibiotic prescriptions: an assessment of patient attitudes, knowledge and advice from health professionals. Australas Med J. 2014;7(1):1–5.

14. Roque F, Soares S, Breitenfeld L, Lopez-Duran A, Figueiras A, Herdeiro MT. Attitudes of community pharmacists to antibiotic dispensing and microbial resistance: a qualitative study in Portugal. Int J Clin Pharm. 2013;35(3):417–24.

15. Chaves NJ, Cheng AC, Runnegar N, Kirschner J, Lee T, Buising K. Analysis of knowledge and attitude surveys to identify barriers and enablers of appropriate antimicrobial prescribing in three Australian tertiary hospitals. Intern Med J. 2014;44(6):568–74.

16. Fleming A, Byrne S, Cullinan S, Bradley C. A qualitative study of antibiotic prescribing practices in Long Term Care Facilities using the Theoretical Domains Framework. Int J Clin Pharm. 2013;35(6):1280.

17. Hogan-Murphy D, Stewart D, McIntosh T, Rajpal P. An exploration of the attitudes and beliefs of doctors on the various barriers and facilitators to implementing antimicrobial stewardship programmes in acute appendicitis. Int J Pharm Pract. 2013;21:23.

18. Huttner B, Harbarth S, Nathwani D. Success stories of implementation of antimicrobial stewardship: a narrative review. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20(10):954–62.

19. James R, Loo S, Avent M, Marshall C, Thursky K, Buising K. A mixed methods study of the barriers and enablers in implementing antimicrobial stewardship programmes in Australian regional and rural hospitals. J Antimicrob Chemother. 2015;70(9):2665–70.

20. Pawluk S, Black E, El-Awaisi A. Strategies for improving antibiotic use in Qatar: a survey of pharmacists’ perceptions and experiences. Int J Pharm Pract. 2015;23(1):77–9.

21. Cambridge Uo. What thresholds should I use for factor loading cut-offs? UK: MRC Cognition and Brain Sciences Unit; 2013 (cited 2017 25/12/2017). 2013-03-08 10:17:27: [FAQ]. http://imaging.mrc-ebu.cam.ac.uk/statswiki/FAQ/thresholds.

22. Sarwar MR, Saqib A, Hitkhar S, Sadig T. Knowledge of community pharmacists about antibiotics, and their perceptions and practices regarding antimicrobial stewardship: a cross-sectional study in Punjab, Pakistan. Infect Drug Res. 2018;11:133–45.

23. Houle SK, Grindrod KA, Chatterley T, Tsuyuki RT. Paying pharmacists for patient care: a systematic review of remunerated pharmacy clinical care services. Can Pharm J = Revue des pharmaciens du Canada. 2014;147(4):209–32.

24. Australia PSo. Australia should follow UK for pharmacists in GP clinics 2016 (updated April 27, 2016; cited 2018 15/01/2018). https://www.psa.org.au/news/australia-should-follow-uk-for-pharmacists-in-gp-clinics.

25. Murray E, Fourie J, Lotts D, Mins M, Schellack N, Bezuidenhout S, Meyer JC. Knowledge and perceptions of antimicrobial stewardship concepts among final year pharmacy students in pharmacy schools across South Africa. South African J Infect Dis. 2016;31(3):84–90.

26. Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Dobele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990–1001.

27. International Pharmaceutical Federation. Updated statement on AMR. The Pharm J; 2017 September 2017 online. http://www.pharmaceutical-journal.com/20203643.article?utm_campaign=2482_PJ_dai ly_alert&utm_medium=email&utm_source=E pharmaceutical%20Journal.

28. Chahine EB, El-Lababidi RM, Sourial M. Engaging pharmacy students, residents, and fellows in antimicrobial stewardship. J Pharm Pract. 2015;28(6):585–91.

29. Sneddon J, Gilchrist M, Wickens H. Development of an expert professional curriculum for antimicrobial pharmacists in the UK. J Antimicrob Chemother. 2015;70(5):1277–80.

30. Nathwani D, Christie P. The Scottish approach to enhancing antimicrobial stewardship. J Antimicrob Chemother. 2007;62(Suppl 1):69–71.

31. Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. Lancet Infect Dis. 2017;17(2):e56–63.